2. Search Result
Search Result
Results for "

Specific uptake

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

5

Peptides

1

Inhibitory Antibodies

9

Natural
Products

5

Isotope-Labeled Compounds

6

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0470
    Neomycin sulfate
    65+ Cited Publications

    		 Environmental Pollutants Antibiotic Phospholipase Bacterial Infection Metabolic Disease Cancer
    Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin sulfate inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin sulfate depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin sulfate can be used for the research of cancer .
    Neomycin sulfate
  • HY-134452
    MeAIB
    4 Publications Verification

    α-(Methylamino)isobutyric acid

    		 Amino acid Transporter Cancer
    MeAIB (α-(Methylamino)isobutyric acid) is a specific?substrate for amino acid transport system A (ATA1). ATA mediate the uptake of short-chain neutral amino acids in a Na +-dependent manner .
    MeAIB
  • HY-14560C
    Reboxetine mesylate
    2 Publications Verification

    FCE20124 mesylate; PNU155950E mesylate

    		 Adrenergic Receptor Neurological Disease
    Reboxetine mesylate (FCE20124 mesylate) is a potent, selective, and specific noradrenaline reuptake inhibitor (NARI) for the research of depression. Reboxetine mesylate inhibits the uptake of norepinephrine, with a Ki of 8 nM .
    Reboxetine mesylate
  • HY-150520
    Neomycin

    		Antibiotic Phospholipase Infection Cancer
    Neomycin, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin is a known phospholipase C (PLC) inhibitor. Neomycin potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin can be used for the research of cancer .
    Neomycin
  • HY-N0642
    α-L-Rhamnose monohydrate

    		Drug Derivative Calcium Channel Metabolic Disease
    α-L-Rhamnose monohydrate is a neutral sugar present in plants, animals, viruses and bacteria. α-L-Rhamnose monohydrate is a ligand for α-L-rhamnose-recognizing lectin sites, trigger intracellular signaling pathways. α-L-Rhamnose monohydrate induces rhaE and rhaA expression as a specific carbon source in Aspergillus nidulans, while glucose inhibits its cellular uptake. α-L-Rhamnose monohydrate induces rapid and transient increases in intracellular free Ca 2+ concentration in normal human dermal fibroblasts .
    α-L-Rhamnose monohydrate
  • HY-Y0148
    10-Hydroxydecanoic acid

    NSC 15139; 10-HDAA

    		 Parasite Autophagy NF-κB Interleukin Related NO Synthase MDM-2/p53 TNF Receptor RANKL/RANK Caspase Infection Neurological Disease Inflammation/Immunology
    10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells .
    10-Hydroxydecanoic acid
  • HY-P99925
    Enoticumab

    REGN421

    		 Notch Metabolic Disease Cancer
    Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .
    Enoticumab
  • HY-P1848
    Pep-1 (uncapped)
    2 Publications Verification

    		 Interleukin Related Cancer
    Pep-1 (uncapped) is a specific ligand of IL-13Ra2. Pep-1 (uncapped) exerts cell penetrating activity through receptor-mediated endocytosis, can cross the blood-tumor barrier (BTB) and target glioma cells. Pep-1 (uncapped) can enhance the uptake of nanoparticles by tumor cells and enhance the cell penetration ability of nanoparticles, and can be used to develop targeted drug delivery systems for glioma .
    Pep-1 (uncapped)
  • HY-120657
    9-PAHSA

    		CGRP Receptor NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA
  • HY-164583
    DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite

    		Phosphoramidites DNA/RNA Synthesis Others
    DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite is an RNA phosphoramidite monomer. DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite allows site-specific introduction of a 2'-O-C22 lipophilic modification at adenosine positions to construct double-stranded RNA (dsRNA) molecules with extrahepatic delivery capability. DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite supports target gene silencing in skeletal muscle, cardiac muscle and adipose tissue by enhancing the lipophilicity and tissue uptake efficiency of dsRNA. DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite can be used for the construction and mechanism research of nucleic acid silencing molecules .
    DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite
  • HY-100968
    GBR 12783 dihydrochloride

    		Dopamine Receptor Neurological Disease
    GBR 12783 dihydrochloride is a specific, potent and selective dopamine uptake inhibitor that inhibits the [ 3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively. GBR 12783 dihydrochloride can improve memory performance and increase hippocampal acetylcholine release in rats .
    GBR 12783 dihydrochloride
  • HY-177435
    FAPI-800CW

    		FAP Inflammation/Immunology
    FAPI-800CW is a near-infrared (NIR) fluorescent-labeled fibroblast activation protein (FAP) inhibitor. FAPI-800CW shows specific uptake in inflamed paws in collagen-induced arthritis (CIA) model mice. FAPI-800CW can be used for in vivo molecular imaging of FAP expression in inflammatory diseases such as rheumatoid arthritis (RA) to monitor joint inflammation and disease activity .
    FAPI-800CW
  • HY-164582
    DMTr-2'-O-C22-rC(Ac)-3'-CE-Phosphoramidite

    		Phosphoramidites DNA/RNA Synthesis Others
    DMTr-2'-O-C22-rC (Ac)-3'-CE-Phosphoramidite is an RNA phosphoramidite monomer. DMTr-2'-O-C22-rC (Ac)-3'-CE-Phosphoramidite enables site-specific introduction of 2'-O-C22 lipophilic modification at cytidine positions during oligonucleotide synthesis, which is used to construct double-stranded RNA (dsRNA) molecules with extrahepatic delivery capability. DMTr-2'-O-C22-rC (Ac)-3'-CE-Phosphoramidite supports target gene silencing in skeletal muscle, cardiac muscle and adipose tissue by enhancing the lipophilicity and tissue uptake efficiency of dsRNA. Construction and mechanism study of DMTr-2'-O-C22-rC (Ac)-3'-CE-Phosphoramidite nucleic acid silencing molecules .
    DMTr-2'-O-C22-rC(Ac)-3'-CE-Phosphoramidite
  • HY-150741B
    FITC-labeled ODN 2216 sodium

    		Toll-like Receptor (TLR) Interleukin Related Inflammation/Immunology
    FITC-labeled ODN 2216 (sodium) is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. FITC-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.
    FITC-labeled ODN 2216 sodium
  • HY-164581
    DMTr-2'-O-C22-rG(ibu)-3'-CE-Phosphoramidite

    		Phosphoramidites DNA/RNA Synthesis Others
    DMTr-2'-O-C22-rG (ibu)-3'-CE-Phosphoramidite is an RNA phosphoramidite monomer for oligonucleotide synthesis. DMTr-2'-O-C22-rG (ibu)-3'-CE-Phosphoramidite enables site-specific introduction of 2'-O-C22 lipophilic modification at guanosine positions to construct double-stranded RNA (dsRNA) molecules with extrahepatic delivery capability. DMTr-2'-O-C22-rG (ibu)-3'-CE-Phosphoramidite supports target gene silencing in skeletal muscle, cardiac muscle and adipose tissue by enhancing the lipid solubility and tissue uptake efficiency of dsRNA. DMTr-2'-O-C22-rG (ibu)-3'-CE-Phosphoramidite can be used for the construction and mechanism research of nucleic acid silencing molecules .
    DMTr-2'-O-C22-rG(ibu)-3'-CE-Phosphoramidite
  • HY-D2281
    FAP Ligand 2

    		FAP Cancer
    FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .
    FAP Ligand 2
  • HY-150741A
    Biotin-labeled ODN 2216 sodium

    		Toll-like Receptor (TLR) Inflammation/Immunology
    Biotin-labeled ODN 2216 (sodium) is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. Biotin-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.
    Biotin-labeled ODN 2216 sodium
  • HY-W770410
    9-PAHSA-13C4

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA- 13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-13C4
  • HY-175014
    LGT-1

    		PD-1/PD-L1 Biochemical Assay Reagents Cancer
    LGT-1 is a PD-L1 ligand. LGT-1 labeled with 18F has an excellent specific uptake in B16-F10 tumor cells, and shows a high tumor uptake but a low liver uptake with good stability in B16-F10 tumor-bearing mice model. LGT-1 can be used as a radiotracer for PET imaging of PD-L1 expression in tumors .
    LGT-1
  • HY-153612
    MMV009085

    		GLUT Parasite Infection Inflammation/Immunology
    MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7) .
    MMV009085
  • HY-158266
    DOTA-PSMA-EB-01

    LNC1003

    		 Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-PSMA-EB-01
  • HY-N5123
    α-L-Rhamnose

    		Endogenous Metabolite Metabolic Disease
    α-L-Rhamnose is a neutral sugar present in plants, animals, viruses and bacteria. α-L-Rhamnose is a ligand for α-L-rhamnose-recognizing lectin sites, trigger intracellular signaling pathways. α-L-Rhamnose induces rhaE and rhaA expression as a specific carbon source in Aspergillus nidulans, while glucose inhibits its cellular uptake. α-L-Rhamnose induces rapid and transient increases in intracellular free Ca 2+ concentration in normal human dermal fibroblasts .
    α-L-Rhamnose
  • HY-179227
    HDAC6 ligand-7

    		HDAC Neurological Disease
    HDAC6 ligand-7 (Compound 16a) is a positron emission tomography (PET) tracer for the deacetylase 6 (HDAC6) enzyme with a Kd value of 1.66 nM. HDAC6 ligand-7 exhibits excellent HDAC6 inhibitory activity, with IC50 values of 2.7 and 3.7 nM for hHDAC6 and mHDAC6, respectively, and has high selectivity for HDAC1/4/7/8. HDAC6 ligand-7 after being radioactively labeled with fluorine-18, [¹⁸F]HDAC6 ligand-7 shows varying degrees of radioactive uptake in PET, which can reflect the specific binding to HDAC6. HDAC6 ligand-7 can be used for the study of HDAC6 imaging .
    HDAC6 ligand-7
  • HY-120657S
    9-PAHSA-d4

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-d4
  • HY-119141
    RH 3421

    		Sodium Channel Neurological Disease
    RH 3421, an insecticidal dihydropyrazole, acts as an inhibitor of sodium channel-specific sodium uptake, blocking the uptake stimulated by Veratridine (HY-N6691), Vatrachotoxin (HY-12549), crude scorpion .
    RH 3421
  • HY-W008610
    GBR 12783

    		Dopamine Receptor Neurological Disease
    GBR 12783 is a specific, potent and selective dopamine uptake inhibitor that inhibits the [ 3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively. GBR 12783 can improve memory performance and increase hippocampal acetylcholine release in rats .
    GBR 12783
  • HY-163079
    AlF-PD-FAPI

    		FAP Cancer
    AlF-PD-FAPI has affinity for FAP , with the IC50 of 0.13 nM, and shows a specific uptake, high internalized fraction, and low cellular efflux in vitro. AlF-PD-FAPI can be used as FAP-targeting tracer .
    AlF-PD-FAPI
  • HY-14560CR
    Reboxetine mesylate (Standard)

    FCE20124 mesylate (Standard); PNU155950E mesylate (Standard)

    		 Reference Standards Adrenergic Receptor Neurological Disease
    Reboxetine (mesylate) (Standard) is the analytical standard of Reboxetine (mesylate). This product is intended for research and analytical applications. Reboxetine mesylate (FCE20124 mesylate) is a potent, selective, and specific noradrenaline reuptake inhibitor (NARI) for the research of depression. Reboxetine mesylate inhibits the uptake of norepinephrine, with a Ki of 8 nM .
    Reboxetine mesylate (Standard)
  • HY-134452R
    MeAIB (Standard)

    α-(Methylamino)isobutyric acid (Standard)

    		 Amino acid Transporter Reference Standards Cancer
    MeAIB (Standard) is the analytical standard of MeAIB. This product is intended for research and analytical applications. MeAIB (α-(Methylamino)isobutyric acid) is a specific substrate for amino acid transport system A (ATA1). ATA mediate the uptake of short-chain neutral amino acids in a Na+-dependent manner .
    MeAIB (Standard)
  • HY-N15726
    Obtusichromoneside C

    		Others Others
    Obtusichromoneside C is a chromone C-glycoside found in the seeds of Cassia obtusifolia. Obtusichromoneside C regulates substance transport by inhibiting substrate uptake of specific transporters (e.g., OAT3, OATP1B3). Obtusichromoneside C is promising for research of drug transport .
    Obtusichromoneside C
  • HY-W194107
    Antitumor agent-152

    		DNA/RNA Synthesis Cancer
    Antitumor agent-152 (Compound 5) is a specific substrate and inhibitor of deoxycytidine kinase (dCK) with anticancer activity. Antitumor agent-152 can inhibit the uptake of 3H-dC in L1210 leukemia cells with an IC50 value of 1.12 μM .
    Antitumor agent-152
  • HY-136659
    Ro 04-5595

    		iGluR Others
    Ro 04-5595 is a selective antagonist with specific activity against the NR2B subunit of the NMDA receptor. Ro 04-5595 exhibits favorable pharmacokinetic properties in in vitro and in vivo studies, with rapid uptake and clearance. Ro 04-5595 exhibits strong binding in NR2B receptor-enriched regions and low binding in the cerebellum. Ro 04-5595 is able to effectively inhibit specific binding, showing high affinity for the NR2B receptor and a clear ranking of binding affinity with a variety of other compounds .
    Ro 04-5595
  • HY-161965
    MK-3168 (12C)

    		FAAH Neurological Disease
    MK-3168 (12C) is a FAAH inhibitor with IC50 values of 1.0, 5.5, 1.7 nM for human, rhesus, rat, respectively. MK-3168 shows good brain uptake and FAAH-specific signal. 11C MK-3168 can be used as FAAH PET tracer .
    MK-3168 (12C)
  • HY-149210
    S1PR1 ligand 1

    		LPL Receptor Others
    S1PR1 ligand 1 (compound 6 h) is a specific S1PR1 ligand with IC50 = 8.7 nM. S1PR1 ligand 1 has good brain uptake. S1PR1 ligand 1 can be labeled with 18F to study the function of S1PR1 in brain diseases .
    S1PR1 ligand 1
  • HY-121659
    DCFBC

    		PSMA Cancer
    DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F 18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer .
    DCFBC
  • HY-169071S
    ATX-1905

    		Phosphodiesterase (PDE) Others
    ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .
    ATX-1905
  • HY-117542
    D595

    		Histone Methyltransferase Neurological Disease
    D595 is a phenylethylamine calcium channel blocker with potent negative inotropic activity. D595 has shown significant efficacy in its corresponding pharmacological studies, especially in inhibiting the uptake of monoamine neurotransmitters. D595 has high affinity in binding to the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). Structural adjustments of D595, especially changes in the hydroxyl stereochemistry, significantly affect its interaction with the transporters, showing a specific preference for stereoisomers .
    D595
  • HY-Y0148R
    10-Hydroxydecanoic acid (Standard)

    NSC 15139 (Standard); 10-HDAA (Standard)

    		 Reference Standards Parasite Autophagy NF-κB Interleukin Related NO Synthase MDM-2/p53 TNF Receptor RANKL/RANK Caspase Infection Neurological Disease Inflammation/Immunology
    10-Hydroxydecanoic acid (Standard) is the analytical standard of 10-Hydroxydecanoic acid. This product is intended for research and analytical applications. 10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells[1][2][3][4][5].
    10-Hydroxydecanoic acid (Standard)
  • HY-120657R
    9-PAHSA (Standard)

    		Reference Standards CGRP Receptor NF-κB Cardiovascular Disease Inflammation/Immunology
    Flumethrin (Standard) is the analytical standard of Flumethrin. This product is intended for research and analytical applications. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA (Standard)
  • HY-144026S
    9-PAHSA-d9

    		CGRP Receptor NF-κB Inflammation/Immunology
    9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-d9
  • HY-120657S1
    9-PAHSA-d31

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-d31
  • HY-P11591
    PDI2

    PSMA-DOTA-PEI2

    		 Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer .
    PDI2
  • HY-D3196
    AG2

    		Fluorescent Dye Cancer
    AG2 is a glucose uptake tracer and two-photon fluorescent probe. AG2 is taken up by cells via glucose-specific transport systems, rather than passive diffusion; it preferentially accumulates in cancer cells and colon cancer tissues compared with normal cells and tissues; it mainly localizes to mitochondria, with a small amount also distributed in the cytoplasm and cell membrane. AG2 can be used for colon cancer research .
    AG2
  • HY-P0036D
    NOTA-Octreotide

    		Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis Cancer
    NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .
    NOTA-Octreotide
  • HY-182746
    RG7388-PEG3-Click-F

    		MDM-2/p53 Drug Derivative Cancer
    RG7388-PEG3-Click-F is a fluorinated analog of the MDM2 inhibitor RG7388 (HY-15676), with an IC50 of 16.8 nM against MDM2. [ 18F]RG7388-PEG3-Click-F exhibits high uptake and specificity in MDM2-expressing myeloma cells, and can be used for non-invasive assessment of MDM2 protein expression levels in tumors .
    RG7388-PEG3-Click-F
  • HY-120433
    BLT-3

    		Scavenger Receptor Class B type I (SR-BI） Inflammation/Immunology
    BLT-3 is an inhibitor of scavenger receptor class B type I (SR-BI) that exerts reversible, non-cell-type-specific inhibitory effects on SR-BI-mediated lipid transport. BLT-3 inhibits SR-BI-mediated selective lipid uptake from HDL as well as cholesterol efflux from cells to HDL. BLT-3 enhances the binding of HDL to SR-BI. BLT-3 is applicable to research related to atherosclerosis and coronary heart disease .
    BLT-3
  • HY-P10792A
    HYNIC-H6F

    		EGFR Cancer
    HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC50 = 11 nM). HYNIC-H6F accumulates in HER2-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in HER2-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of HER2-positive breast cancer in mouse models and allows evaluation of HER2 expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research .
    HYNIC-H6F
  • HY-182345
    NOTA-MK0159

    		CD38 Cancer
    NOTA-MK0159 is a NOTA (HY-134418) and MK0159 (HY-150508) conjugate. NOTA-MK0159 inhibits human and mouse CD38 with IC50 values of 72.58 and 7.55 nM. NOTA-MK0159 coupled with radioactive elements acts as a imaging agent with specific uptake in CD38-positive multiple myeloma cells, enabling noninvasive whole-body assessment of CD38 expression in multiple myeloma xenografts. NOTA-MK0159 can be used for the research of multiple myeloma .
    NOTA-MK0159
  • HY-182944
    GATT-44

    		GABA Receptor Neurological Disease
    GATT-44 is a blood-brain barrier-permeable, selective GABA transporter 1 (GAT-1) ligand with an IC50 of 126 nM. GATT-44 shows selectivity for GAT-2, GAT-3 and BGT-1 subtypes, and undergoes copper-mediated 18F-radiofluorination. The radiolabeled GATT-44 ([ 18F]GATT-44) exhibits brain uptake, metabolic stability and high GAT-1 binding specificity in non-human primates. GATT-44 is applicable for research on neurodegenerative and neuropsychiatric diseases .
    GATT-44
  • HY-181285
    MAT2A ligand 1

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A ligand 1 is a MAT2A ligand inhibitor (IC50=29.5 nM) and PET tracer that crosses the blood-brain barrier. MAT2A ligand 1 enables non-invasive imaging of MAT2A-expressing tumors, with rapid tumor uptake equilibrium, a high tumor-to-muscle ratio, and specific tumor-binding properties. MAT2A ligand 1 is applicable to research related to non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioblastoma, pancreatic adenocarcinoma, urothelial carcinoma, breast cancer, and prostate cancer .
    MAT2A ligand 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: